Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
Tag: remdesivir
Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries since
Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis
The aim of the study was evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults with COVID-19. 52
Cyclodextrins in the antiviral therapy
This review discusses the basic properties of the different cyclodextrin derivatives, their potential in antiviral formulations, and the prevention and
Combinatory treatment of Covid-19 with remdesivir and the repurposed drugs fluoxetine and itraconazole
The antiviral potential of the antifungal itraconazole and the antidepressant fluoxetine was tested on the production of infectious SARS-CoV-2 particles
Peripheral infiltration of remdesivir in 3 patients with COVID-19: Case series and discussion
The scientists from Netherland reported 3 cases on remdesivir infiltration in patients with Covid-19. In the first case, a 91-year-old
Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?
The authors summarized the potential cutaneous side effects of remdesivir, a nucleoside/nucleotide analog treatment and compared them with those observed
Targeting Lipid Rafts as a Strategy Against Coronavirus
Lipid rafts are functional membrane microdomains containing sphingolipids, including gangliosides, and cholesterol. These regions are characterized by highly ordered and
Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: characterization of electrospun- and lyophilized formulations
Vekluryâ„¢ by Gilead Sciences, Inc., containing antiviral drug, remdesivir (REM) has received emergency authorization in the USA and in Europe
Reduced mortality rate and shorter time for clinical improvement upon Remdesivir treatment
This retrospective comparative effectiveness research study was conducted from March 4 to August 29, 2020, in a 5-hospital health system